Merck's Oral PCSK9 Inhibitor Achieves 55.8% LDL-C Reduction in Clinical Trial

Mercks investigational oral PCSK9 inhibitor, enlicitide decanoate, achieved a remarkable 55.8% reduction in low-density lipoprotein cholesterol, highlighting its potential in combating cardiovascular disease.

• In a Phase 3 trial, Mercks oral PCSK9 inhibitor, enlicitide decanoate, led to a 55.8% reduction in low-density lipoprotein cholesterol compared to placebo over 24 weeks.
• The results of the CORALreef Lipids study were presented at the American Heart Association, emphasizing the drugs potential impact on patients with coronary artery disease.
• The significant reduction in LDL-C could lower the risk of serious events such as myocardial infarction and stroke, addressing a critical need in cardiovascular disease management.